†#Authors contributed equally to this manuscript One Sentence Summary: Synchronized patterns of development of the immune system and microbiome in pre-and full-term infants are disrupted as a marker of respiratory disease.
Introduction
Human newborns are highly susceptible to severe illness and chronic respiratory morbidity with frequent viral respiratory infections (1, 2). Additionally, infants born prematurely have up to a 50% risk for recurrent cough and rehospitalization in the first year, most frequently associated with viral infections, and even a portion of healthy-born full-term infants will suffer from similar morbidity (3) . Because T cells are critical in clearing viral pathogens and supporting the formation of protective memory, elevated risk in newborns has traditionally been attributed to either immunodeficiency secondary to the immature adaptive immune systems or, alternatively, to injury induced by an exuberant inflammatory response (4) . Our recent prospective study of 277 preterm (PT, < 37 0/7 weeks gestation) and full-term FT (>/= 37 0/7 weeks gestation) infants in the Prematurity and Respiratory Outcomes Program (PROP), showed that CD31+ CD4+ T cells, a population enriched for recent thymic emigrants, were protective against chronic respiratory morbidity in infants born prematurely (5, 6) . In particular, the persistence of low CD31+ CD4+ T cell frequency in PT infants at approximately 40 weeks postmenstrual age (PMA), suggesting delayed immune maturation, corresponded to higher risk for persistent respiratory disease (PRD) in the first year. We have also reported characteristic development of both the nasal and gut microbiota associated with prematurity, day of life, and PMA (7, 8) . Two recent studies demonstrate that the nasopharyngeal microbiome and virome together predict infant respiratory tract infection but fail to take the state of immune development into account (9, 10) . Early adaptation or maladaptation of the immune system to early colonizers undoubtedly relates to an infant's risk for respiratory morbidity, but characterizing the relative importance of immune development in the context of microbial exposures individually and synergistically has been elusive.
A growing number of studies hint at a complex, developmentally-determined immune program influenced by early clinical exposures and microbial colonization (11) (12) (13) . For example, Olin et al. recently demonstrated major shifts in the bulk immune cell populations over the first 3 months of life that followed a predictable pattern according to days of life (14) . Early gut dysbiosis, indicated by particularly low microbiota diversity, was associated with an altered balance of immune cell populations, though deeper phenotyping of T cells was not reported. We propose that understanding interrelated infant T cell and microbiota developmental trajectories will reveal markers of predisposition to respiratory illness and shape causative models that link early prenatal and postnatal events, including preterm birth and microbiota and immune development, to long-term health outcomes.
The objectives of this current study were to construct a comprehensive model that describes concordant and discordant developmental trajectories of both T cells and the microbiota in the first year; to characterize the relationship between microbiota and T cell variation after adjusting for birth events and gestational age; and, finally, to assess the impact of abnormal T cell-microbiota trajectories on risk for PRD and respiratory infection. Here we report, for the first time, that while the development of T cells and microbiota of the gut and respiratory tract are indeed strongly coupled to PMA, some T cell-microbiota associations exist independently of gestational age at birth and PMA, and atypical or mistimed development of either the microbiome or T cells relative to host age is a marker of respiratory morbidity during infancy.
Results

Study Design and Demographics
Neonatal subjects (n=267) born 23-42 weeks gestational age (GA) were recruited within 7 days of birth at the University of Rochester from 2012-2016, as part of the NIAID-sponsored Prematurity, Respiratory, Immune Systems and Microbiomes study (PRISM) (Fig. 1) . In all, 122 preterm (PT, < 37 0/7 weeks gestation) and 80 full-term (FT, ≥ 37 0/7 weeks gestation) subjects completed the study to 12 months of age corrected for premature birth and were categorized as having or not having the primary outcome persistent respiratory disease (PRD) using previously published criteria (15) . Among these, 52 PT subjects (43%) and 17 FT subjects (21%) met the criteria for PRD. Sufficient blood to perform T cell phenotyping by flow cytometry was collected from 55% of subjects at birth, 61% of subjects at NICU discharge, and 38% at 12 months. Complete (two staining panels) immunophenotyping for all three timepoints was performed on 25% of subjects, and 63% of subjects had complete immunophenotyping for at least one timepoint. For microbiota profiling, after sample processing, 16S rRNA sequencing, quality control, and removing subjects without any immunophenotyping data, 149 subjects yielded 1748 usable nasal samples and 143 subjects yielded 1899 usable rectal samples. Finally, included for immunome-nasal microbiota and immunome-rectal microbiota association analyses, respectively ( Supplementary Tables 1-2 A total of 119 full term and 148 preterm infants were recruited at birth. Swabs were obtained of the nares and rectum to be used for 16S rRNA sequencing (microbiota) weekly in the NICU prior to discharge, monthly post-discharge, and when symptoms of respiratory illness were present. Blood was collected at birth (cord blood), hospital discharge or 36-42 weeks postmenstrual age (whichever was first), and again at 12 months. The 12 month outcome of persistent respiratory disease was determined based on quarterly surveys assessing respiratory morbidity. Respiratory and gut microbiota samples were assessed by 16S rRNA sequencing as previously described (8) . Swabs were obtained on study enrollment, at weekly intervals prior to initial hospital discharge, and monthly following hospital discharge through one year of life.
Respiratory and Gut Microbiota Progression by Postmenstrual Age
Additional samples were collected during acute respiratory illnesses between discharge and one
year. Unweighted Unifrac distances between all samples within each body site were computed as a measure of b-diversity and were used to perform principal coordinate analysis (PCoA). The first principal coordinate (PC1) accounted for 10.8% of the total variation seen in the gut microbiota and 12.2% of the total variation in nasal microbiota. Visualization and annotation of these results revealed that for both body sites, overall sample variation reflected subjects' maturity at birth and PMA at sampling ( Fig. 2A-2B 
T cell development in newborns
We next sought to characterize associations between PMA and T cell phenotype. T cell phenotyping (Tphe) was performed by flow cytometry using blood samples collected at birth, hospital discharge (or 36-42 weeks PMA, whichever came first) and 12 months of gestationally corrected age. Cells were thawed and prepared for staining with a T cell phenotyping panel ("Tphe", total 414 samples). A separate intracellular cytokine antibody panel was also used to stain cells stimulated in vitro with Staphylococcal Enterotoxin B (SEB) ("ICS", total 404 samples) (staining panel details available in Supplementary Fig 1) . The clustering algorithm To visualize a longitudinal trajectory of T cells, uniform manifold approximation and projection (UMAP) was applied to each sample, without regard to subject-level clinical features.
Each sample's Tphe and ICS profiles combined in this case represented a single feature in the UMAP (Fig. 4B) , revealing a pattern similar to the microbial progression; PT and FT T cell phenotype and function clustered separately at birth, less so at discharge, and appeared fully convergent by 12 months. Metaclusters that were different between PT and FT subjects were observed almost exclusively at birth and discharge timepoints ( Fig. 4D , Supplementary Fig. 2 ).
Many PT-associated populations were Tregs, memory and effectors. Tphe metaclusters enriched in FT were mostly naïve and Vmems with high CD31+ and IL7ra expression. ICS metaclusters enriched in PT were naïve CD45RA+ T cells with either TNFa, IL-2 or no detectable cytokines.
FT ICS metacluster cytokine function was characterized by high IL-8 and IL-2.
The majority of metaclusters could serve as simple linear predictors of PMA ( Fig. 4C ).
Both CD4+ and CD8+ T cells displayed a TE phenotype at the earliest PMA, which then transitioned to predominantly naive T cells, followed by CM and then Vmem by one year PMA.
The nature and abundance of cytokine functions varied with both GA and PMA. Activated TNFa+, IL-2+ or cytokine null CD4+ and CD8+ metaclusters were higher at the earliest PMA, after which IL-8 became the dominant cytokine. IL-8-positive subpopulations showed minimal TNFa expression, suggesting that these functions may be counter-regulated within the cell.
Canonical polarized (CD45RA-, IFNg, IL-4, IL-17 or CD107a) T cells were frequent only at the 12 month timepoint. The exception to the delayed polarized T cell development was a single IL-4-positive CD8+ metacluster, which was only seen at the youngest PMA. Utilizing the three timepoints typically captured for each subject, we identified 10 metaclusters with non-monotone V-or inverted-V trajectories from birth to 12 months in PT samples ( Fig. 4E , Supplementary   Fig. 3 ). Most frequently, these metacluster abundance followed a V-shaped trajectory: decreasing sharply from birth to 37 weeks PMA, followed by a slower recovery from 37 weeks to one year.
This pattern was seen in several memory CD4+ and CD8+ metaclusters, indicating a transiently activated T cell phenotype at birth that resolves under more homeostatic conditions. Two CD4+ ICS metaclusters (5 and 9), which were IL-8-positive, had inverted-V trajectories. 
12-month
Defining immune state types
To characterize T cell trajectory during infancy, we partitioned samples into immune state types (ISTs) based on the abundances of all metaclusters, using the same DMM modeling technique that was applied to the microbiota samples. We defined 7 T cell phenotype immune state types (Tphe ISTs) and 8 ICS immune state types (ICS ISTs), which were numbered according to their order of occurrence and exhibited strong associations with PMA (ANOVA, r 2 = 0.86 and 0.69, respectively) ( Fig. 5A-5D ). Tphe1-Tphe4 and ICS1-ICS4 were only seen in samples drawn at birth and discharge. The phenotypic and functional trajectory revealed by ISTs is consistent with that found using individual metaclusters ( Fig 5E-F) .
Two Tphe ISTs (Tphe5 and Tphe6) were present at all three timepoints and in both GA groups, suggesting that clinical exposures, as opposed to development, drive the phenotypes.
Tphe5 was most notably marked by the abundance of atypical early activated (CD31+, CD45RO-, CCR7-, CD28-) CD8+, CD4+ CM, and Treg subpopulations. Vmems were lower in Tphe5, suggesting perturbed homeostasis. This heterogeneity, reflecting activated conventional and regulatory T cells, indicates that subjects exhibiting Tphe5 at birth or discharge experienced some degree of prenatal immune priming. In fact, chorioamnionitis and/or exposure to antenatal antibiotics raised the odds of a subject ever entering Tphe5 by 7-fold (95% CI 1.0-54, p<.05) and 4-fold (95% CI 1.1-13, p<.03), respectively, in a joint logistic regression model that adjusted for GA, sex, race, mode of delivery, and premature rupture of membranes ( Supplementary Fig. 4 ).
Tphe6, which was more common at 12 months, was marked by high abundance of CD57+ and cytotoxic CD8+ metaclusters. CD57+ CD8+ T cells have been associated with T cell exhaustion due to chronic viral infection (23, 24) . In our cohort 60% of subjects ever entering Tphe6 tested positive for CMV at 6 or 12 months, while CMV occurred in less than 7% of Tphe6 negative subjects (odds ratio 10.2, p<.0001). These results demonstrate the utility of T cell clustering to distinguish atypical from normal T cell developmental trajectory, and in identifying clinical factors that perturb normal immune development in infants.
Early-life immunity and subsequent microbiome state type
We next hypothesized that some immune and microbial features would exhibit correlations beyond what their mutual dependence on host age could explain. In order to test this, we modeled the number of days a subject spent in a given CST and the odds the CST occurring in a subject at all each as a function of one of their immunological parameters (IST or metacluster abundance at a particular time point), adjusting for gestational age at birth and mode of delivery. We fit models on all pairwise combinations of CSTs and immunological parameters.
The significant results of these tests were visualized as networks ( Fig. 6A, Supplementary Fig.   5A ). Among the models of CST duration, of the potential 6318 possible associations between the 26 CSTs and 243 immunological parameters, only 10 Tphe and no ICS metaclusters achieved statistical significance after multiple test correction. CST-associated CD4+ metaclusters preceded, but CD8+ metaclusters followed, the average onset of their associated CST, suggesting the directionality of these relationships. Among the models of whether or not a CST would occur at all, of the 15 total ISTs, only 3 (Tphe1, Tphe3 and Tphe5) were significantly correlated with a single CST (nCST 8). The most striking finding in the network was that early entry into Tphe5 (n=25 subject-samples) precluded a subject ever entering into nCST 8 (Fig. 6B ). The nCST 8 dominant taxa Allociococcus was virtually absent in preterm samples collected prior to 40 weeks PMA, but appeared soon after, with stationary mean abundance post-discharge ( Fig.   6C ).
We then performed a similar analysis fitting survival models using the same covariates and time to first reach a given CST as the outcome. Interestingly, gCSTs, CD8+ T cell populations and ICS metaclusters appeared significant more often in these models than in the duration and occurrence models ( Supplementary Fig. 5B ). Infants with higher TNFa or IFNg+ naïve CD8+ T cell metacluster frequencies at discharge and one year showed delayed entry into the Streptotoccus-dominant nCST 4. The gCST 9 (Bifidobacterium and Bacterioides low), in which there were a higher number of PT samples, was delayed in subjects discharged with higher frequencies of effector CD8+ populations. Similarly, the occurrence of gCST 3, the most diverse and mature gCST common prior to discharge and the earliest gCST in which Clostridia are prevalent, was accelerated in subjects exhibiting Tphe2 at discharge ( Supplementary Fig. 6 ).
These results indicate that precocious T cell function may impact developmental timing and rate of progression of the gut microbiota, rather than promoting persistent differential abundance of specific taxa as is observed in the airway.
Illness, Microbiome and Nascent T Cell Immunity
Previous reports indicate that Alloiococcus in the respiratory tract is positively associated with antibiotic-resistant otitis media, but also with less severe respiratory illness in children (25, 26) . Because the predominance of Alloiococcus is the distinguishing feature of nCST 8, and the occurrence of nCST 8 was precluded by the occurrence of Tphe5 in early life, we sought to assess the relationship between Alloiococcus abundance in the nose, acute respiratory illness, and early immunopheotype, controlling for multiple confounders. To identify episodes of respiratory illness post-NICU discharge, infants were scored by parents using a self-reported modified COAST score when respiratory symptoms arose (27) . If the threshold of 3 was met, an in-person study visit was initiated, during which symptom scores were reviewed, nasal and rectal swabs were obtained, and a physical exam was performed.
As expected, the Tphe5 immunophenotype at birth or discharge was associated with diminished Alloiococcus abundance in the nose across all post-discharge timepoints, yielding a 7-fold reduction (3-14 fold, 95% CI, p-value < 0.001; Fig. 6C ), while controlling for day of life, gestational age at birth, mode of delivery, and repeated sampling of subjects. Additionally, we found a 40% reduction in the odds of a sample being taken during acute illness for every 10% increase in Alloiococcus relative abundance (log odds = -3.52 ± 2.19, 95% CI, p-value = 0.002), controlling for confounders as above. Considering the joint effects of acute illness and Tphe5 occurrence at birth or discharge as predictors in the same model, we found that both were associated with reduced Alloiococcus abundance, (log ratios -0.91 ± 0.42 and -1.90 ± 0.80, respectively, 95% CI; p-values < 0.001; Fig. 6D ). However, despite negative associations between Tphe5 and Alloiococcus abundance, and Alloiococcus abundance with illness, Tphe5
was not significant as a predictor of illness, either by itself (log odds = 0.54 ± 0.70, 95% CI, pvalue = 0.131) or in conjunction with Alloiococcus relative abundance (log odds = -0.35 ± 0.71, 95% CI, p-value = 0.328), controlling for confounders in both cases. Together, these results
show that early immune priming, as seen by early entry into Tphe5, may shape respiratory microbiota development, which is subsequently strongly linked with acute respiratory illnesses. 
Immune/Microbial Developmental Index and Respiratory Outcome
Observing that rare T cell-microbiota interactions occurring independently of PMA impacted respiratory morbidity led us to hypothesize that mistimings in development of T cells or microbiota increased the risk of PRD. To test this hypothesis, we developed a quantitative model of "normal" PMA, as a function of T cell and microbiota composition. We trained two sparse regression models that used the metacluster and OTU abundance vectors to predict log2transformed PMA at sample collection. Holding out a subject's longitudinal record, the crossvalidated models strongly predicted PMA using either T cell metaclusters (r 2 =0.77) or bacterial taxa (r 2 =0.65) ( Fig. 7A ). For each subject, the fitted intercepts of these models -predicted PMA the microbiome intercept and immune slope had largest variable importance scores. In exploring the functional relationship between PRD and these factors, we observed that immature microbiota at term equivalent PMA increased the risk of PRD by over 2-fold, and this effect was magnified in subjects with accelerated T cell maturation (Fig. 7C) . Together with the Tphe5-Alloiococcus findings, these results support the notion that timing of T cell and microbiome maturation relative to an infant's age play an integral role in promoting or interfering with respiratory health. 
Discussion
Birth marks the commencement of a dynamic interplay between innate developmental programming, colonization and assembly of the microbiome, and differentiation and maturation of the adaptive immune system which influences health from infancy through adulthood. In healthy infants, this process balances the accommodation of commensal microbiota, appropriate immune response to pathogens, and functional maturation of the organs at the interface between human host and environment. By developing longitudinal models of microbiota composition and T cell populations, we were able to establish conceptually and analytically tractable representations of these systems, and to interrogate their maturation and development, revealing several key findings. First, T cells and microbiota exhibit structured patterns of progression synchronized by postmenstrual age, with pronounced differences between pre-and full-term infants in very early life and a tendency towards convergence by the end of one year. Furthermore, within the framework of development driven by PMA, interactions occur between T cell population profiles and microbiota community structure. Finally, atypical or asynchronous immune and microbiota development are markers of respiratory disease and health outcomes. To our knowledge, this is the first study to successfully model the influence of this triad of T cell, microbiota, and host development on clinical outcomes in a cohort of both preterm and full-term human infants.
The ability to predict a subject's PMA based on their T cell phenotype is strong evidence that developmental state is a key driving factor in immune maturation, which is further reinforced by convergence of PT and FT phenotypes over time. Characterizing the immune trajectory during infancy revealed greater heterogeneity than previously appreciated, especially between PT and FT subjects and even within their predominantly naïve T cell pool. As an example, early PT and FT ISTs were both enriched for naïve T cell subpopulations with high CCR7 and CD28 and low CD45RO expression. Yet, CD31, IL-7ra and CXCR5 naive metaclusters were differentially abundant between PT and FT, implicating differences in cell survival and provision of B-cell help. Our results are aligned with previous studies demonstrating that PT infants have higher proportions of CD45RO+ T cells in their cord blood (28, 29) . Many of the PT-enriched CD4+ CD45RO+ subpopulations, however, were of a Treg phenotype, confirming prior studies showing that activated fetal naive T cells have a propensity towards Treg differentiation (30) (31) . The low abundance of virtual memory cells in PT subjects at birth is contrary to earlier speculation that in utero T cell activation in PT is caused by homeostatic expansion alone (32) (33) (34) . The direct correlation between gestational age and IL-8+
T cells is notable in that the Olin study shows enhanced plasma IL-8 in PT when compared to FT (14) . Our focus on T cells specifically, rather than secreted mediators in plasma, sheds light on a T cell-specific trajectory during infancy that may be distinct from the innate compartment and is largely, but not entirely, dependent on postmenstrual age.
Our results also reinforce the central role of host development in driving microbiota progression over time, with premature infants exhibiting distinct patterns of microbiota composition in very early life and a convergence between pre-and full-term infants over the first year. Despite this general tendency towards convergence in T cells and microbiota, the occurrence of certain state types reflect an enduring influence of GA (e.g. gCST 4, 6, and 8, Together, the microbiota of the airway and gastrointestinal tract, and their interaction with one another and with host immune function, constitute the gut-lung axis, a system increasingly implicated in respiratory morbidity (35, 36) . Notably, while the relationship between immune development and the gut microbiome has featured prominently in literature, we identified more, stronger associations between T cell populations and nasal microbiota. Of particular interest is the association observed between the occurrence of Tphe5 early in life (at birth or discharge), and the subsequent abundance of Alloiococcus in the nose. Alloiococcus is a common post-discharge colonizer, but its abundance is dramatically reduced in infants who pass through Tphe5 early in life, with nCST 8 -the Alloiococcus dominated nCST -being entirely absent from these subjects. The additional observation that Alloiococcus is substantially diminished during acute respiratory illness reveals a previously undescribed connection between T cell development at birth, post-discharge airway colonization, and susceptibility to respiratory infection throughout the first year of life.
By defining developmental indices based on microbiota and T cell populations, we establish that maturity at term and rate of maturation over the first year are indicators of disease outcome at one year (PRD). Specifically, precocious immune development in conjunction with an immature microbiome at term corresponds to substantially elevated risk of PRD, while either one of these factors by themselves has an attenuated effect. This indicates that mistimed or discordant maturation between the microbiome and immune system is a correlate of respiratory morbidity. Previous reports have used age, microbiota, or immune variables as independent factors in predicting respiratory outcome (2, 5, 25, 37) . These studies do not address the possibility that a newborn's immune system is not simply deficient, but rather under normal developmental conditions, is uniquely balanced to provide protection against novel pathogens while minimizing immunopathology. Exposures that accelerate or delay the normal maturation of T cells and microbiota during infancy, such as in utero infection promoting the early occurrence of Tphe5, may disrupt this age-specific balance that has served human evolution so well.
The PRISM study results demonstrate the strength of large, prospective observational studies in discovering early risk factors for disease. There are also limitations to our study design that should be acknowledged. The greatest challenge in conducting immune surveillance studies in newborns is obtaining sufficient blood volumes to perform comprehensive assays and adequate sampling frequencies to inform robust longitudinal models. Our results show that substantial changes in the immune system occur between NICU discharge and 12 months, and without the benefit of intensive interim sampling, it is difficult to comprehensively account for all clinical factors that may shape an individual's immune trajectory. However, our discoveries can be used inform future studies focusing on the timing and specific shifts in immune populations and microbiota that impact respiratory outcomes, such as Tphe5 and Alloiococcus. It will also be important for future models to address other events, including distinguishing respiratory viral infections and changes in nutrition, and how these exposures either coordinate or interfere with normal developmental trajectories. Despite the inherent challenges, using human observational studies is a powerful approach to scientific discovery which can reveal practical insights into the systems influencing health and disease that are not readily accessible in controlled experimental settings or animal models. However, translation of these discoveries into medical management will benefit from carefully controlled interventional studies. Specifically, our results suggest markers of immune and microbiota development which may indicate susceptibility to respiratory infection and risk of chronic respiratory morbidity. Additionally, the interaction between these two systems invites the possibility of intervention, whereby biotic therapy or immunotherapy applied to one system could potentially be used to modulate the other.
Finally, the evidence that an infant's health is influenced by the these two systems remaining synchronous with postnatal development underscores the need to tread cautiously when considering interventions that may disrupt this normal balance.
Materials and Methods
Study Design
All study procedures were approved by the University of Rochester Medical Center REDCap (37, 38) , then integrated with laboratory results using the URMC Bio Lab Informatics Server, a web-based data management system using the open source LabKey Server (39) . Blood was collected at birth, time of NICU discharge or 36-42 weeks PMA (whichever occurred first), and at 12 months of life. We collected 2729 gut (842 from NICU and 1887 post-discharge), and 2210 nasal (619 from NICU and 1591 post-discharge) usable microbiota samples longitudinally from 139 pre-term and 98 full-term infants. From the PRISM study cohort, fecal (rectal) and nasal material was collected from pre-term infants (23 to 37 weeks gestational age at birth (GAB)) weekly from the first week of life until hospital discharge, and then monthly through one year of gestationally corrected age. Rectal and nasal samples were collected from full-term infants at enrollment and monthly through one year. Additionally, rectal and nasal samples were collected from all infants whenever they exhibited symptoms of acute respiratory illness after discharge from the hospital. Symptoms of acute respiratory illness prompting sample collection were summarized by the primary caregiver using a symptom COAST (Childhood Origins of Asthma) score sheet (1). Parents were instructed to notify the study team if the infant had symptom score of three or greater. All blood samples generating usable data were included in all analyses. For training the PMA predictions models (described below), all microbiota samples were used. For all other analyses, microbiota samples from subjects that did not have any usable data from blood were excluded.
Flow Cytometry Methods
Sample collection, isolation, storage, thawing, stimulation and staining for flow cytometry was performed as detailed in a previously published method (40) . In short, cord blood and peripheral blood mononuclear cells were isolated via Ficoll centrifugation, cryopreserved and stored in liquid nitrogen, and rapidly thawed and washed with pre-warmed RPMI-1640 (10% FBS and 1x L-glutamine); thawing was done in 'subject-balanced' batches (equal mix of pre and full-term subjects, each with three time points) and an aliquot of each freshly thawed sample was (Supplementary Fig. 1 ).
Samples were acquired on a BD LSRII (core facility instrument QC-ed daily with BD CS&T beads); PMT voltages normalized per run to pre-determined/optimized 'Peak-6' (Spherotech) median fluorescence values. R-based packages and scripts were used for all postacquisition processing and analysis. Reading of raw .fcs files, compensation, transformation, and subsetting/writing of .fcs files was performed using flowCore (41) 
Microbiota Identification
Microbiota sample collection and storage techniques, genomic DNA extraction and background control methods were as previously published (7) . Raw data from the Illumina MiSeq was first converted into FASTQ format 2 × 312 paired-end sequence files using the bcl2fastq program (v1.8.4) provided by Illumina. Format conversion was performed without demultiplexing, and the EAMMS algorithm was disabled. All other settings were default. Samples were multiplexed using a configuration described previously (43) . The extract_barcodes.py script from QIIME (v1.9.1) (44) was used to split read and barcode sequences into separate files suitable for import into QIIME 2 (v2018.11) (45) which was used to perform all subsequent read processing and characterization of sample composition. Reads were demultiplexed requiring exact barcode matches, and 16S primers were removed allowing 20% mismatches and requiring a matching window of at least 18 bases. Cleaning, joining, and denoising were performed using DADA2 (46) : reads were truncated (forward reads to 260 bps and reverse reads to 240 bps for rectal V3-V4 samples and forward reads to 275 bps and reverse reads to 260 bps for nasal V1-V3 samples), error profiles were learned with a sample of one million reads per sequencing run, and a maximum expected error of two was allowed. Taxonomic classification was performed with custom naïve Bayesian classifiers trained on target-region specific subsets of the August, 2013 release of GreenGenes (47) . Sequence variants that could not be classified to at least the phylum level were discarded. Sequencing variants observed fewer than ten times total, or in only one sample, were discarded. Rectal samples with fewer than 2250 reads and nasal samples with fewer than 1200 reads were discarded. Phylogenetic trees were constructed for each body site using MAFFT (48) for sequence alignment and FastTree (49) for tree construction. For the purposes of b-diversity analysis, rectal and nasal samples were rarefied to depths of 2250 and 1200 reads, respectively, and the Unweighted Unifrac (50) metric was applied. For each CST, each of these immunological parameters (metacluster relative abundances and IST) at each of the three time points when the immune system was sampled (birth, discharge, and one year) was assessed independently, and are hereafter referred to as the immunological variables of interest (VOIs).
CST occurrence patterns were related to immunological VOIs by testing three types of associations between every CST-VOI combination at the level of individual subjects, while controlling for mode of delivery (MOD), gestational age at birth (GAB) and, in model (i) only (see below), the number of microbiome samples (sampling_intensity) that were collected from an individual. These models differed in the aspect of CST occurrence that was modeled as the outcome. Model (i) tests associations between the VOI and whether or not a CST occurs at all in an individual; (ii) tests associations between the VOI and how persistent a CST is in an individual; and (iii) tests associations between the VOI and the days to first occurrence of a CST in an individual. Model (i) was tested using logistic regression with VOI, MOD, GA and the number of microbiome observations from a given individual as the sampling intensity. The outcome indicated whether or not a given CST was ever observed in the individual. We tested the VOI association by dropping that term and calculating a likelihood ratio test. Model (ii) was tested using a quasi-Poisson regression model with MOD, GA, and the VOI as covariates, and total number of days the subject was assigned to any CST as an offset. The number of days a subject was assigned to a given CST was the outcome and was calculated by summing the interval lengths between CST change points. Intervals were calculated from midpoint to midpoint on the sampled days of life. At birth, subjects were placed in the first observed CST if the first sample occurred within 14 days of life, otherwise the first interval was excluded.
Subjects were assumed to remain in their final observed CST for an interval equal to half the interval length between the penultimate and ultimate sample. Significance of the VOI was assessed as in model (i). Model (iii) was tested using interval censored, accelerated log logistic failure time models (R package icenReg v2.0.9) (54) with MOD, GA, and the VOI as covariates and the interval preceding the first observation of a given CST as the outcome. For gCST 1 and nCST 1, which on average were the earliest CSTs, we modeled the interval preceding the first observation of a CST other than NAS 1 or REC 1. For each CST, only subjects that were ever observed in that CST at some point were included. Significance was assessed based on Wald test p-values of the terms in the fitted full models.
For models (i)-(iii), subjects with fewer than one sample taken per 30 NICU-days or fewer than six samples post discharge were excluded. We filtered immune VOI with fewer than ten observations, and CSTs present in fewer than 10% of the remaining observations. Numerical covariates were converted into z-scores, except GA which we modeled as (GA − 37)/37.
Within each model (i)-(iii), multiple testing across all CSTs and VOIs was corrected for using the Benjamini-Hochberg method at 10% FDR. Cross validation for tuning and prediction. We tuned the model and estimated its performance using cross-validation by holding out a subject's entire longitudinal record. We tuned the elastic net alpha in [0, 1] and lambda in [.001, .5] parameters by randomly selecting 50 combinations of (alpha, lambda) and evaluating the test mean-square error (MSE) via 5-fold cross-validation. After finding a minimizing pair of (alpha, lambda), the model was refit with 10-fold cross-validation. For each subject i, this provides two sequences of fitted values, representing the log2-transformed PMA prediction. For instance, for the microbiome, we have +, -= 01 2 14 These are transformed into a quantity similar to a z-score by subtracting the median of 1 , 1 over subjects i, and dividing by its conditional standard error se( 1 ) or se( 1 ).
Prediction of PRD.
We used random forest classification models to predict PRD using 
